Cartesian Therapeutics, Inc.
RNAC
Rangering i aksjer
#18408
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Aksjekurs
$6.27
Sist synkronisert: 2026-10-16
Markedsverdi
$189.70M
Endring (1 dag)
-4.71%
Endring (1 år)
839.61%
Land
US
Handel Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Markedsverdi av Cartesian Therapeutics, Inc.(RNAC)
Markedsverdi: $189.70M
Per October 2026 har Cartesian Therapeutics, Inc. en markedsverdi på $189.70M. Dette gjør Cartesian Therapeutics, Inc. til det 18408th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Cartesian Therapeutics, Inc. fra 2016 til 2026
RNAC sammenlignet med topp 5 mest populære stocks
